PureTech Health (LON:PRTC) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

PureTech Health plc (LON:PRTC) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 129.20 and traded as low as GBX 124.53. PureTech Health shares last traded at GBX 125.61, with a volume of 358,950 shares changing hands.

Wall Street Analyst Weigh In

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 508 target price on shares of PureTech Health in a research note on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, PureTech Health has a consensus rating of “Buy” and an average price target of GBX 508.

PureTech Health Price Performance

The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The firm has a market capitalization of £302.33 million, a price-to-earnings ratio of -2.70 and a beta of 0.79. The stock has a 50 day moving average price of GBX 129.14 and a two-hundred day moving average price of GBX 126.97.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Robert Lyne purchased 36,500 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were bought at an average cost of GBX 119 per share, for a total transaction of £43,435. Also, insider Sharon Barber-Lui purchased 29,868 shares of PureTech Health stock in a transaction dated Tuesday, July 7th. The shares were acquired at an average cost of GBX 119 per share, for a total transaction of £35,542.92. In the last 90 days, insiders purchased 147,849 shares of company stock valued at $17,594,031. 13.35% of the stock is owned by insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.